A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.
በ AI የተሰራ ምስል

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

በAI የተዘገበ በ AI የተሰራ ምስል እውነት ተፈትሸ

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Jorge Carrasco, president of the Chilean Society of Pediatrics, said flu vaccine coverage for children under five stands at only 60.54%, below the 80% target.

በAI የተዘገበ

Australia has recorded 230 cases of diphtheria and one related death this year. The outbreak is concentrated in remote Indigenous communities across several states.

Researchers led by Flinders University have identified the molecular trigger behind a rare blood clotting disorder linked to adenovirus-based COVID-19 vaccines and infections. The immune system mistakes an adenovirus protein for the human blood protein PF4, leading to harmful antibodies in extremely rare cases. The discovery, detailed in the New England Journal of Medicine, paves the way for safer vaccines.

በAI የተዘገበ

Small-scale farmers in South Africa's Eastern Cape have voiced frustration over inaccessible foot-and-mouth disease (FMD) vaccines, saying they have sought help from the Department of Agriculture without success.

Researchers at Northwestern University have developed a more effective therapeutic vaccine for HPV-related cancers by rearranging components in a DNA-based nanoparticle. This structural adjustment significantly enhances the immune system's ability to target and destroy tumors. The findings, published in Science Advances, highlight the importance of molecular arrangement in vaccine design.

በAI የተዘገበ

In a recent meeting with the Cuban president, health experts presented progress on the Finlay Vaccine Institute's pneumococcal conjugate vaccine development program. This effort, led for over 20 years, aims to protect children and older adults from severe diseases caused by Streptococcus pneumoniae. The heptavalent Quimi-Vio® vaccine is already registered and shows positive results in reducing mortality.

 

 

 

ይህ ድረ-ገጽ ኩኪዎችን ይጠቀማል

የእኛን ጣቢያ ለማሻሻል ለትንታኔ ኩኪዎችን እንጠቀማለን። የእኛን የሚስጥር ፖሊሲ አንብቡ የሚስጥር ፖሊሲ ለተጨማሪ መረጃ።
ውድቅ አድርግ